Ahmedabad-based pharma major Cadila Healthcare (Zydus Cadila) is planning to start clinical trials on children aged 5 years and above soon for its DNA-plasmid technology-based Covid-19 vaccine, claimed a senior official.
Meanwhile, the company is awaiting approval from the Drugs Controller General of India (DCGI) for its vaccine ZyCoV-D. It has sought approval for use in children above 12 years, and has already submitted safety and tolerability data from the phase 2 clinical trials and has generated data on 1,000 adolescents (between 12 to 18 years) from its phase 3 trials too. The 1,000-volunteer data will be submitted with the